At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
nab-sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating nab-sirolimus for Colorectal Cancer Metastatic. Completed, enrolled 60 participants across 6 sites.
Detailed Summary
A phase 1/2 multi-center investigation of nab-sirolimus (also known as ABI-009, nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with metastatic colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer Metastatic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJul 2018
Primary CompletionAug 2022
Study CompletionAug 2022
TodayJul 2026
First PostedFeb 20, 2018
Enrollment StartJul 1, 2018
Primary CompletionAug 16, 2022
Study CompletionAug 26, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.4 years ago
Interventions
nab-sirolimusdrug
nab-sirolimus combined with mFOLFOX6 + bevacizumab